More recently, Bian et al. were able to define MYC-high and MYC-low PDAC subtypes using a set of 16 transcriptional targets of c-MYC in patient-derived tumour xenograft (PDTX) models, with the MYC-high subgroup demonstrating increased sensitivity to the BET inhibitor JQ1 [138]. Here, MYC is linked to neoplasm.